Future Product Development Clause Samples

The Future Product Development clause outlines the rights and obligations of the parties regarding the creation and ownership of products or technologies developed after the agreement is signed. Typically, this clause specifies whether new inventions, improvements, or derivative works made in the future will be owned jointly, individually, or assigned to one party, and may address how intellectual property rights are handled for these future developments. Its core function is to prevent disputes over ownership and usage rights of innovations that arise after the initial agreement, ensuring clarity and protecting the interests of all parties involved.
Future Product Development. The Parties enter into this AGREEMENT to establish a long term relationship. SYMPHONIX shall therefore include SIEMENS and SIEMENS shall include SYMPHONIX as a participant in its process for the definition and specification of future products. SYMPHONIX shall make all future SYMPHONIX PRODUCTS available to SIEMENS for the distribution in the TERRITORY, and such SYMPHONIX PRODUCTS shall be marketed by SIEMENS as soon as practical after they become available.
View SourceView Similar (2)
Future Product Development. 9.1 To the extent ATS elects to have ErySave participate in the development of future Products that employ the PARSUS Technology in the Licensed Field, the parties shall share equally the cost of all future development of and improvements to such future Products, including the cost of all patenting arising out of inventions relating to such future Products. If ATS does not elect to have ErySave participate, then ATS shall pay such costs. As indicated in Section 12.5, all such inventions and the associated patent and other intellectual property rights shall be and remain the property of ErySave and shall fall within the scope of the License, as provided in this Agreement. ATS and its agents, employees, contractors and representatives shall execute such assignments as ErySave may consider necessary or desirable to implement its property interest. 9.2 To the extent ATS elects to have ErySave participate in the development of such future Products, the parties shall consult with one another regarding such future Product development work and shall, acting reasonably, establish agreed plans and budgets for such work.
View Source
Future Product Development. Sprint and Supplier will meet quarterly, or more often if required by Sprint, to track the progress of the roadmap product development and to negotiate pro-active solutions, as needed.
View Source
Future Product Development. The Parties acknowledge that nothing in this Agreement shall commit Kodak to future development of this or any other product, Including new hardware, features, support tools or maintenance releases.
View Source
Future Product Development. 4.14.1. Should Medtech request any development work for future eye care products, Pharmacare shall have the right to undertake such development work, subject to the parties entering into a written Product Development Agreement ("PDA"), which will, inter alia, provide: 4.14.1.1. for payment of the development costs on completion of the development; 4.14.1.2. that development shall be regarded as complete once Pharmacare has delivered to Medtech 3 (three) validation batches of the developed product that meet all agreed specifications as set out in the FDA, and are approved by Medtech quality assurance, such approval not to be unreasonably withheld. 4.14.2. The parties record that any future eye care products developed by Pharmacare at Medtech's request during the term will be supplied by Pharmacare to Medtech according to the terms contained in this exclusive supply agreement subject to mutual agreement as to prices, volumes and other commercial terms.
View Source
Future Product Development. The Parties agree to collaborate with each other, in preference to collaborations with other parties, in any future development of new Products in the Enzyme Immunoassay ("EIA") instrumentation field on the following terms. (a) SIGMA shall inform IVAX DIAGNOSTICS in writing whether or not SIGMA wants to implement a new product idea offered by IVAX DIAGNOSTICS within three (3) months after the date SIGMA receives a written concept of the new product idea. If SIGMA wants to implement a new product idea presented by IVAX DIAGNOSTICS, the parties will negotiate in good faith to agree on the terms of developing and distributing such new product. If IVAX DIAGNOSTICS does not receive such written notice from SIGMA, or if the parties are unable to reach agreement on the terms of a development and distribution agreement under similar terms and conditions of this Agreement within three (3) months after SIGMA gives notice of its interest, IVAX DIAGNOSTICS shall be free to develop and distribute this new product, either on its own or in a collaboration with another party. However, such research and development shall not negatively affect IVAX DIAGNOSTICS' performance under this Agreement. (b) IVAX DIAGNOSTICS shall inform SIGMA in writing whether or not IVAX DIAGNOSTICS wants to implement a new product idea offered by SIGMA within three (3) months after the date IVAX DIAGNOSTICS received a written concept of the new product idea. If IVAX DIAGNOSTICS does not receive such written notice from SIGMA, or if the parties are unable to reach agreement on the terms of a development and distribution agreement under similar terms and conditions of this Agreement, within three (3) months after SIGMA gives notice of its interest, IVAX DIAGNOSTICS shall be free to develop and distribute this new product, either on its own or in collaboration with another party. However, such research and development shall not negatively affect SIGMA's performance under this Agreement.
View Source
Future Product Development. ‌ 18.1 The Parties acknowledge that nothing in this Agreement shall commit Kodak to future development of this or any other product, Including new hardware, features, support tools or maintenance releases. 18.2 The Parties acknowledge that any changes requested by MMR to the Product will require separate written amendments to this Agreement. 18.3 MMR acknowledges that the Product uses some hardware components that may obsolesce and agrees to hold Kodak harmless for Product changes required to replace obsolesced parts. MMR will accept Product with said hardware changes as equivalent to the original design. Original design shall be embodied by the non co-branded product at time of initial shipping approval, available under separate catalog number (not covered by this Agreement) . 18.4 MMR acknowledges Kodak’s right to further develop this Product or substantially similar Products at Kodak’s sole discretion. In the event Kodak releases a future generation of the Product and at Kodak’s sole discretion and approval, MMR may be allowed to satisfy an remaining unit volume commitments under this Agreement with the newer product. [***]
View Source
Future Product Development 
View Source

Related to Future Product Development

  • Product Development (a) Supplier may develop enhancements it intends to incorporate into the BioGlue Surgical Adhesive during the term of this Agreement that have potential application to the Company Product (“Enhancements”). Unless otherwise agreed by the parties, at least once every six months during the Term, representatives of each of BioForm and Supplier shall hold a meeting in accordance with Sections 4.4 and 8.4 (the “Product Development Meeting”) at which Supplier will present Enhancements for BioForm to consider for application to the Company Product. At such Product Development Meeting, BioForm will also present its marketing plans (pursuant to Section 4.4) for the period and any information or feedback that BioForm reasonably believes may lead to Improvements. Within 30 calendar days following each Product Development Meeting, Supplier shall deliver a notice to BioForm (the “Enhancements Notice”) that shall describe the Enhancements that were presented by Supplier at such Product Development Meeting. Within 30 calendar days following receipt of the Enhancements Notice, BioForm may notify Supplier in writing if BioForm elects that any Enhancement described in the Enhancements Notice shall become an Improvement. If BioForm does provide such notice to Supplier during such 30-calendar day period, then BioForm and Supplier shall agree on a timeline for implementation of the Improvement in new Product Specifications for Company Product. If BioForm does not provide such a notice, said Enhancement shall not be implemented into the Company Product. The Enhancements Notice may also describe any potential Enhancements presented by Supplier at the Product Development Meeting, but BioForm shall not be required to take any action under this Section 8.4 with respect to such potential Enhancements until such time as they are presented by Supplier as Enhancements at a future Product Development Meeting. All Enhancements and potential Enhancement information provided by Supplier shall be considered Supplier Confidential Information. (b) From time to time, each party may request the other party to participate in joint projects to develop Improvements. Neither party is obligated to participate in such projects, and in each **** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. instance, each party’s decision whether to participate will be made in such party’s sole discretion. If both parties mutually agree to participate in such a project (a “Program”), the parties will promptly prepare a mutually agreeable written development agreement specifying the development activities to be performed by and the research and development tasks assigned to each party (the “Development Agreement”). All allocation of Intellectual Property rights with respect to any Program will be set forth in writing in the Development Agreement. (c) In the absence of a Development Agreement, (i) BioForm and Supplier shall retain joint ownership of Intellectual Property rights in which there is joint inventorship by BioForm (or its Affiliates) and Supplier, as determined in accordance with United States patent law, with Supplier’s rights in such joint ownership being subject to the license rights of BioForm under this Agreement, (ii) any Intellectual Property rights related to the Company Products, Enhancements, and Improvements that are created solely by employees or consultants of Supplier during the Term shall be considered to be Intellectual Property rights of Supplier, subject to the license rights of BioForm under this Agreement, and (iii) any Intellectual Property rights related to the Company Products and Improvements that are created solely by employees or consultants of BioForm or any of its Affiliates during the Term shall be considered to be Intellectual Property rights of BioForm. BioForm hereby grants to Supplier a perpetual, royalty free, world-wide, nonexclusive license to Supplier under such Blocking Intellectual Property to make, use, and sell such Intellectual Property outside the Field. “Blocking Intellectual Property” for the purposes of Section 8.4(c)(iii) shall mean Intellectual Property necessary for Supplier to make, use, or sell SA Product.

  • Research Primary Investigator as part of a multi-site study (25 points) • Co-Investigator as part of a multi-site study (20 points) • Primary Investigator of a facility/unit based research study (15 points) • Co-Investigator of a facility/unit based research study (10 points) • Develops a unit specific research proposal (5 points) • Conducts a literature review as part of a research study (5 points)

  • Project Development a. Collaborate with COUNTY and project clients to identify requirements and develop a project Scope Statement. a. Develop a Work Breakdown Structure (WBS) for each project. b. Evaluate Scope Statement to develop a preliminary cost estimate and determinate whether project be vendor bid or be executed under a Job Order Contract (JOC).

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Program Development NWESD agrees that priority in the development of new applications services by WSIPC shall be in accordance with the expressed direction of the WSIPC Board of Directors operating under their bylaws.